EA201691290A1 - BENZODIAZEPINOVA DERIVATIVES, COMPOSITIONS AND METHODS FOR THE TREATMENT OF COGNITIVE DISTURBANCE - Google Patents
BENZODIAZEPINOVA DERIVATIVES, COMPOSITIONS AND METHODS FOR THE TREATMENT OF COGNITIVE DISTURBANCEInfo
- Publication number
- EA201691290A1 EA201691290A1 EA201691290A EA201691290A EA201691290A1 EA 201691290 A1 EA201691290 A1 EA 201691290A1 EA 201691290 A EA201691290 A EA 201691290A EA 201691290 A EA201691290 A EA 201691290A EA 201691290 A1 EA201691290 A1 EA 201691290A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- cognitive impairment
- compositions
- derivatives
- treatment
- age
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Это изобретение относится к бензодиазепиновым производным, композициям, включающим терапевтически эффективные количества этих бензодиазепиновых производных, и способам применения этих производных или композиций в лечении когнитивного нарушения, связанного с нарушениями центральной нервной системы (ЦНС). В частности, оно относится к применению агониста рецептора α5-содержащей ГАМКА (например, положительного аллостерического модулятора рецептора α5-содержащей ГАМКА), как описано здесь, в лечении когнитивного нарушения, связанного с нарушениями центральной нервной системы (ЦНС), у пациента или лица, для которого существует риск развития этого нарушения, включая, без ограничения, пациентов, страдающих, или подвергающихся риску его развития, возрастным когнитивным нарушением, умеренным когнитивным нарушением (MCI), вызывающим нарушение памяти MCI (aMCI), возрастным ухудшением памяти (AAMI), возрастным снижением когнитивных способностей (ARCD), деменцией, болезнью Альцгеймера (AD), продромальной AD, посттравматическим стрессовым расстройством (PTSD), шизофренией, биполярным расстройством, боковым амиотрофическим склерозом (ALS), когнитивным нарушением, связанным с терапией рака, умственной отсталостью, болезнью Паркинсона (PD), нарушениями аутического спектра, синдромом хрупкой X хромосомы, синдромом Ретта, компульсивным поведением и наркотической зависимостью.This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of these benzodiazepine derivatives, and methods of using these derivatives or compositions in the treatment of cognitive impairment associated with disorders of the central nervous system (CNS). In particular, it relates to the use of an α5-containing GABAA receptor agonist (for example, a positive allosteric modulator of an α5-containing GABAA receptor), as described here, in the treatment of cognitive impairment associated with disorders of the central nervous system (CNS) in a patient or person for which there is a risk of developing this disorder, including, without limitation, patients suffering or at risk of developing it, age-related cognitive impairment, mild cognitive impairment (MCI) causing memory impairment MCI (aMCI), age-related memory impairment (AAMI), age-related cognitive decline (ARCD), dementia, Alzheimer's disease (AD), prodromal AD, post-traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (IL) cognitive impairment associated with cancer therapy, mental retardation, Parkinson's disease (PD), autistic spectrum disorders, fragile X chromosome syndrome, Rett syndrome, compulsive behavior, and drug addiction.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462075743P | 2014-11-05 | 2014-11-05 | |
PCT/US2014/071644 WO2015095783A1 (en) | 2013-12-20 | 2014-12-19 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201691290A1 true EA201691290A1 (en) | 2016-11-30 |
EA039381B1 EA039381B1 (en) | 2022-01-20 |
Family
ID=80685586
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201691290A EA039381B1 (en) | 2014-11-05 | 2014-12-19 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
Country Status (1)
Country | Link |
---|---|
EA (1) | EA039381B1 (en) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE180475T1 (en) * | 1990-09-21 | 1999-06-15 | Rohm & Haas | DIHYDROPYRIDAZINONES AND PYRIDAZINONES AS FUNGICIDES |
EP0586551A1 (en) * | 1991-05-24 | 1994-03-16 | E.I. Du Pont De Nemours And Company | Arthropodicidal anilides |
EA201390710A1 (en) * | 2010-11-15 | 2013-12-30 | Эйджинбайо, Инк. | DERIVATIVES OF BENZODIAZEPINA, COMPOSITIONS AND METHODS FOR THE TREATMENT OF COGNITIVE DISTURBANCE |
-
2014
- 2014-12-19 EA EA201691290A patent/EA039381B1/en unknown
Also Published As
Publication number | Publication date |
---|---|
EA039381B1 (en) | 2022-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019010577A (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment. | |
EA201890090A1 (en) | DERIVATIVES OF BENZODIAZEPINA, COMPOSITIONS AND METHODS FOR THE TREATMENT OF COGNITIVE DISTURBANCE | |
EA201991497A1 (en) | Benzodiazepine derivatives, compositions and methods for the treatment of cognitive impairment | |
EA201390710A1 (en) | DERIVATIVES OF BENZODIAZEPINA, COMPOSITIONS AND METHODS FOR THE TREATMENT OF COGNITIVE DISTURBANCE | |
EA202190076A1 (en) | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATMENT OF COGNITIVE DISORDERS | |
GEP20207149B (en) | Allosteric modulators of nicotinic acetylcholine receptors | |
AU2019268069A1 (en) | Methods and compositions for improving cognitive function | |
AR085219A1 (en) | 6-CICLOALQUIL-PIRAZOLOPIRIMIDINONAS FOR THE TREATMENT OF CNS DISORDERS | |
EA201391106A1 (en) | NEW HETEROCYCLIC DERIVATIVES | |
EA201390712A1 (en) | PYRIDAZIN DERIVATIVES, COMPOSITIONS AND METHODS OF TREATING COGNITIVE DISTURBANCE | |
EA201491116A1 (en) | DERIVATIVES 6-DIFTORMETYL-5,6-DIGIDRO-2H- [1,4] OXAZIN-3-AMINE | |
EA201290764A1 (en) | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | |
EA202091020A1 (en) | SUBSTITUTED IMIDAZOPYRIDINAMIDES AND THEIR APPLICATION | |
MA39145B1 (en) | Piperazine derivatives having multimode activity against pain | |
MX2017008083A (en) | 2,3,4,5-tetrahydropyridin-6-amine and 3,4-dihydro-2h-pyrrol-5-ami ne compound inhibitors of beta-secretase. | |
EA201792575A1 (en) | PHARMACEUTICAL COMPOSITIONS OF LEVETIRACETAMA OF PROLONGED FREEDOM | |
EA201691831A1 (en) | HETEROAROMATIC COMPOUNDS AND THEIR APPLICATION AS DOPAMINE D1 LIGANDS | |
EA201592277A1 (en) | DERIVATIVES 4-AMINO-6-PHENYL-5,6-DIHYDROIMIDAZO [1,5-A] PYRAZINE AS BETA SECRETASE INHIBITORS | |
MX2022007725A (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment. | |
IN2013DN11328A (en) | ||
EA201890460A1 (en) | COMPOSITIONS AND METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISORDERS | |
MA47595A (en) | TREATMENT METHODS FOR NEURODEGENERATIVE DISORDERS | |
EA201691788A1 (en) | HETEROAROMATIC COMPOUNDS AND THEIR APPLICATION AS DOPAMINE D1 LIGANDS | |
EA201591021A1 (en) | 4-HYDROXY-2-METHIL-5- (PROPAN-2-ILIDEN) CYCLOGEX-3-ENEKARBALDEHYDE IN PREVENTION AND TREATMENT OF COGNITIVE, NEURODEGETERATIVE OR NEURAL DISEASES | |
EA201890769A1 (en) | 2,3,4,5-TETRAHYDROPYRIDIN-6-AMINE DERIVATIVES |